By mid-2012, Almirall plans to begin clinical studies on a new inhaled drug for the treatment of COPD called LAS190792, the company has announced. The drug is a dry powder formulation of a dual, long-acting Muscarinic Antagonist β2 Agonist (MABA). The product will be Almirall’s third inhalation drug developed in its Genuair multi-dose DPI.
A statement from the company says, “The MABA franchise (MABA and MABA/ICS combination) offer the convenience of different mechanisms of action in one inhaler therapy, and is envisaged to become a future block buster in COPD.” It goes on to tout the benefits of MABA compounds over LABA/LAMA combinations “in that MABA/ICS combinations can be developed with a reasonable size development programme.”
Read the Almirall press release.
